Table 3.
Stratified associations between rs4939827 and rs12953717 and risk of colon cancer
| Proximal |
Distal |
|||||
|---|---|---|---|---|---|---|
| Controls, n | Cases, n | OR (95% CI) | Controls, n | Cases, n | OR (95% CI) | |
| rs4939827 | ||||||
| TT | 503 | 206 | 1.00 | 503 | 218 | 1.00 |
| TC | 992 | 348 | 0.85 (0.69–1.04) | 992 | 367 | 0.86 (0.70–1.05) |
| CC | 492 | 172 | 0.82 (0.64–1.04) | 492 | 164 | 0.73 (0.58–0.94) |
| P trend | 0.11 | <0.01 | ||||
| P heterogeneity* | 0.72 | |||||
| rs12953717 | ||||||
| CC | 676 | 235 | 1.00 | 676 | 235 | 1.00 |
| CT | 928 | 346 | 1.07 (0.88–1.30) | 928 | 355 | 1.10 (0.90–1.34) |
| TT | 327 | 143 | 1.26 (0.98–1.62) | 327 | 161 | 1.41 (1.10–1.81) |
| P trend | 0.10 | <0.01 | ||||
| P heterogeneity* | 0.76 | |||||
| No family history | Family history | |||||
| rs4939827 | ||||||
| TT | 454 | 377 | 1.00 | 49 | 80 | 1.00 |
| TC | 897 | 643 | 0.86 (0.72–1.02) | 95 | 130 | 0.87 (0.54–1.39) |
| CC | 450 | 312 | 0.79 (0.64–0.97) | 42 | 48 | 0.71 (0.40–1.27) |
| P trend | 0.02 | 0.25 | ||||
| P heterogeneity* | 0.76 | |||||
| rs12953717 | ||||||
| CC | 619 | 424 | 1.00 | 57 | 79 | 1.00 |
| CT | 834 | 628 | 1.11 (0.94–1.30) | 94 | 126 | 0.90 (0.56–1.44) |
| TT | 295 | 276 | 1.40 (1.13–1.72) | 32 | 56 | 1.20 (0.66–2.16) |
| P trend | <0.01 | 0.64 | ||||
| P heterogeneity* | 0.57 | |||||
| No recent aspirin/NSAID use | ||||||
| rs4939827 | ||||||
| TT | 300 | 297 | 1.00 | 201 | 158 | 1.00 |
| TC | 558 | 520 | 0.93 (0.76–1.14) | 433 | 247 | 0.74 (0.56–0.97) |
| CC | 306 | 267 | 0.86 (0.68–1.09) | 184 | 90 | 0.60 (0.43–0.85) |
| P trend | 0.22 | <0.01 | ||||
| P heterogeneity* | 0.08 | |||||
| rs12953717 | ||||||
| CC | 396 | 359 | 1.00 | 278 | 141 | 1.00 |
| CT | 535 | 503 | 1.02 (0.84–1.23) | 391 | 245 | 1.27 (0.97–1.67) |
| TT | 198 | 219 | 1.22 (0.96–1.56) | 128 | 111 | 1.69 (1.20–2.38) |
| P trend | 0.14 | <0.01 | ||||
| P heterogeneity* | 0.10 | |||||
| Men | ||||||
| rs4939827 | ||||||
| TT | 261 | 257 | 1.00 | 242 | 200 | 1.00 |
| TC | 535 | 430 | 0.84 (0.67–1.05) | 457 | 343 | 0.87 (0.68–1.10) |
| CC | 267 | 201 | 0.76 (0.59–0.99) | 225 | 159 | 0.77 (0.58–1.02) |
| P trend | 0.04 | 0.07 | ||||
| P heterogeneity* | 0.97 | |||||
| rs12953717 | ||||||
| CC | 373 | 280 | 1.00 | 303 | 223 | 1.00 |
| CT | 484 | 413 | 1.10 (0.89–1.35) | 444 | 341 | 1.09 (0.87–1.37) |
| TT | 170 | 196 | 1.48 (1.13–1.92) | 157 | 136 | 1.27 (0.95–1.71) |
| P trend | <0.01 | 0.12 | ||||
| P heterogeneity* | 0.51 | |||||
| <65 y | ||||||
| rs4939827 | ||||||
| TT | 216 | 186 | 1.00 | 287 | 271 | 1.00 |
| TC | 371 | 314 | 1.01 (0.78–1.30) | 621 | 459 | 0.77 (0.63–0.95) |
| CC | 209 | 160 | 0.85 (0.63–1.14) | 283 | 200 | 0.72 (0.56–0.93) |
| P trend | 0.30 | <0.01 | ||||
| P heterogeneity* | 0.36 | |||||
| rs12953717 | ||||||
| CC | 284 | 211 | 1.00 | 392 | 292 | 1.00 |
| CT | 346 | 313 | 1.22 (0.96–1.56) | 582 | 441 | 1.01 (0.83–1.24) |
| TT | 141 | 134 | 1.29 (0.95–1.75) | 186 | 198 | 1.42 (1.10–1.84) |
| P trend | 0.07 | 0.02 | ||||
| P heterogeneity* | 0.86 | |||||
*
Risk estimates adjusted for age, center, race, sex, BMI, long-term activity level, average number of cigarettes per day, recent aspirin/NSAID use, dietary calcium and energy intake.